拓新药业
(301089)
| 流通市值：29.70亿 | | | 总市值：41.32亿 |
| 流通股本：9097.55万 | | | 总股本：1.27亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 325,753,716.96 | 218,756,705.1 | 108,322,506.68 | 835,509,951.28 |
| 营业收入 | 325,753,716.96 | 218,756,705.1 | 108,322,506.68 | 835,509,951.28 |
| 二、营业总成本 | 349,459,875.73 | 230,768,163.87 | 111,604,696.36 | 517,162,283.47 |
| 营业成本 | 242,077,660.34 | 165,051,401.37 | 79,986,578.97 | 351,952,513.76 |
| 税金及附加 | 5,189,793.22 | 2,983,628.25 | 1,277,369.64 | 13,019,674.91 |
| 销售费用 | 9,524,506.16 | 6,026,921.16 | 2,100,833.34 | 9,828,891.09 |
| 管理费用 | 65,788,241.8 | 42,924,862.24 | 20,722,760.06 | 94,474,128.17 |
| 研发费用 | 28,913,083.62 | 16,168,269.04 | 8,246,051.34 | 51,249,522.21 |
| 财务费用 | -2,033,409.41 | -2,386,918.19 | -728,896.99 | -3,362,446.67 |
| 其中:利息费用 | - | - | 620.52 | 337,069.98 |
| 其中:利息收入 | 2,264,292.77 | 1,817,543.8 | 487,280.89 | 3,288,967.15 |
| 加:公允价值变动收益 | -463,661.31 | -544,779.12 | -704,998.3 | 546,870.44 |
| 加:投资收益 | 2,963,289.62 | 1,953,769.65 | 1,453,695.62 | 6,569,233.69 |
| 资产处置收益 | - | - | -4,909.59 | - |
| 资产减值损失(新) | - | - | - | -10,768,156.06 |
| 信用减值损失(新) | 3,156,184.84 | 2,418,933.91 | 2,385,995.35 | -4,485,090.22 |
| 其他收益 | 10,901,554.5 | 7,034,864.21 | 2,629,281.78 | 11,473,406.45 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -7,148,791.12 | -1,148,670.12 | 2,476,875.18 | 321,683,932.11 |
| 加:营业外收入 | 148,190.73 | 83,163.16 | 29,957.52 | 1,422.95 |
| 减:营业外支出 | 3,896,564.18 | 267,749.53 | 54,627.14 | 5,151,985.27 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -10,897,164.57 | -1,333,256.49 | 2,452,205.56 | 316,533,369.79 |
| 减:所得税费用 | -8,243,385.44 | 446,066.6 | 383,823.73 | 73,460,635.41 |
| 六、净利润 | -2,653,779.13 | -1,779,323.09 | 2,068,381.83 | 243,072,734.38 |
| 持续经营净利润 | -2,653,779.13 | -1,779,323.09 | 2,068,381.83 | 243,072,734.38 |
| 归属于母公司股东的净利润 | -2,653,779.13 | -1,779,323.09 | 2,068,381.83 | 243,072,734.38 |
| (一)基本每股收益 | -0.02 | -0.01 | 0.02 | 1.93 |
| (二)稀释每股收益 | -0.02 | -0.01 | 0.02 | 1.93 |
| 八、其他综合收益 | - | - | - | -2,126,356.94 |
| 归属于母公司股东的其他综合收益 | - | - | - | -2,126,356.94 |
| 九、综合收益总额 | -2,653,779.13 | -1,779,323.09 | 2,068,381.83 | 240,946,377.44 |
| 归属于母公司股东的综合收益总额 | -2,653,779.13 | -1,779,323.09 | 2,068,381.83 | 240,946,377.44 |
| 公告日期 | 2024-10-26 | 2024-08-24 | 2024-04-23 | 2024-04-23 |
| 审计意见(境内) | | | | 标准无保留意见 |